Agranulocytosis (neutropenia) associated with levamisole in cocaine in British Columbia

Cases of agranulocytosis associated with the use of cocaine containing levamisole were identified in British Columbia in 2008 following an alert from Alberta.[1] From early 2008 to February 2011, 45 cases were reported by physicians throughout BC, including at least three deaths. 

Historically, levamisole was used as an immunomodulating agent to treat some cancers, autoimmune diseases, and nephrotic syndrome, but was replaced over time by more effective drugs with less adverse effects.[2-4] Levamisole was also used as a vet­erinary antihelminthic agent, but has not been available in Canada for any purpose since 2005.[5]

Levamisole is known to cause agranulocytosis in 3% to 10% of exposed persons and is associated with the development of cutaneous necrosis and vasculitis, often involving a purpuric eruption on earlobes and cheeks.[1],[6] The US recently reported that 69% of cocaine seized at its borders contains levamisole.[7]

Public Health in BC continues to receive reports of agranulocytosis related to levamisole in cocaine. Current surveillance of this condition consists of voluntary reporting by BC physicians using a standard case re­port form, which is collated at the BC Centre for Disease Control (BCCDC), and review of data from the BC Coroner’s Service. More cases have been reported in females (53%) and among First Nations (58%). 

Smoking crack cocaine (rock) is the most common route of cocaine administration identified by cases.[1] There are likely additional unreported cases; a review of Alberta laboratory data identified cases as far back as 2006, and anecdotal reports of cases have been re­ceived in BC without an associated report form.

Agranulocytosis is suspected in persons with cocaine use and signs of rapidly progressing infection (i.e., skin abscesses, pneumonia). Diagnostic testing includes complete blood count and differential to identify neutropenia. If the neutrophil count is <1.0 per 10[9] cells/L and the patient has signs of active infection, urgent hospital ad­mission and infectious work-up with blood cultures is required. 

Management includes hematology referral and administration of broad spectrum antibiotics (e.g., Piperacillin/Tazo­bac­tam, Imipenem or Ceftazidime) and Filgrastim (G-CSF). Recovery generally occurs in 7 to 10 days, but close monitoring is required. Recurrence is common; neutropenia has recurred in about half of cases when re-exposed, and two cases have had seven or more episodes reported.

BCCDC is also investigating genetic markers and behavioral risk factors for the development of levamisole-associated neutropenia. Markers under investigation include the major his­tocompatibility complex haplotype HLA-B27, which has a strong association with other autoimmune conditions such as ankylosing spondylitis, and is thought to be a predisposing factor for the development of anti­neutrophil antibodies and subsequent neu­tropenia. Patients who give in­form­ed consent are asked to complete a questionnaire and provide a saliva sample for genetic-marker analysis; four age, sex, and ethnicity-matched cocaine-using controls will be recruited.

If you suspect that one of your patients may have agranulocytosis sec­ondary to cocaine contaminated by levamisole, please complete a provincial reporting form available at www.bccdc.ca/cocaine for both first-time and repeat episodes. General information on agranulocytosis secondary to cocaine contaminated with levami­sole and information on the study can also be found on this website.


References

1. Knowles L, Buxton JA, Skuridina N, et al. Levamisole tainted cocaine causing severe neutropenia in Alberta and British Columbia. Harm Reduct J 2009;6:30. PubMed Abstract.
2. Drew S, Carter B, Nathanson D, et al. Levamisole-associated neutropenia and autoimmune granulocytotoxins. Ann Rheum Dis 1980;39:59-63. PubMed Abstract.
3. Barbano G, Ginevri F, Ghiggeri G, et al. Dis­seminated autoimmune disease during levamisole treatment of nephrotic syndrome. Pediatr Nephrol 1999;13:602-603. PubMed Abstract.
4. Macdonald JS. Adjuvant therapy of colon cancer. CA Cancer J Clin 1999;49:202-219. PubMed Abstract.
5. Wiens M, Son W, Ross C, et al. Cocaine adulterant linked to neutropenia. CMAJ 2010;182:57-59. PubMed Abstract.
6. Han C, Sreenivasan G, Dutz JP, et al. Reversible retiform purpura: A sign of cocaine use. CMAJ 2011; early release 14 March 2011. 
7. Centers for Disease Control and Prevention (CDC). Agranulocytosis associated with cocaine use—Four states, March 2008–November 2009. Morb Mortal Wkly Rep 2009;58:1381-1385. PubMed Abstract.

hidden


This article is the opinion of the BCCDC and has not been peer reviewed by the BCMJ Editorial Board.
Dr Buxton is a physician epidemiologist and the harm reduction lead at the BC Centre for Disease Control. She is co-chair of the BC Harm Reduction Strategies and Services Committee and principal investigator of a study on pharmacogenetic interactions in cocaine users who develop neutropenia from levamisole-tainted cocaine. Ms Kuo is a federal field epidemiologist currently positioned at the BC Centre for Disease Control, Epidemiology Services. She is coordinating the study on pharmacogenetic interactions in cocaine users who develop neutropenia from levamisole-tainted cocaine. Dr Purssell is an associate professor at the University of British Columbia and the medical director of the BC Drug and Poison Information Centre, located at the BC Centre for Disease Control.

Jane Buxton, MD, FRCPC, Margot Kuo, MPH, Roy Purssell, MD, FRCPC. Agranulocytosis (neutropenia) associated with levamisole in cocaine in British Columbia. BCMJ, Vol. 53, No. 4, May, 2011, Page(s) 169 & 205 - BCCDC.



Above is the information needed to cite this article in your paper or presentation. The International Committee of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.

About the ICMJE and citation styles

The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.

An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.

BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:

  • Only the first three authors are listed, followed by "et al."
  • There is no period after the journal name.
  • Page numbers are not abbreviated.


For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit www.icmje.org

BCMJ Guidelines for Authors

Leave a Reply